Design Therapeutics (DSGN) Cash from Operations (2020 - 2026)
Design Therapeutics (DSGN) reported Cash from Operations of 16431000.0 for Q1 2026, up 2.13% on a YoY basis from 16087948.85 in Q1 2025, and down 37.31% sequentially from 11966000.0 in Q4 2025.
Design Therapeutics (DSGN) Cash from Operations (2020 - 2026) Analysis & Trends
Design Therapeutics (DSGN) has 7 years of Cash from Operations data on file, last reported at 16431000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 2.13% year-over-year to 16431000.0; the trailing twelve-month figure through Mar 2026 stood at 54000000.0 (down 13.79% YoY), and the FY2025 full-year result was 54358000.0, down 26.11% from the prior year.
- Cash from Operations eased to 16431000.0 in Q1 2026, from 11966000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 9546000.0 in Q3 2024 to a low of 17424000.0 in Q1 2023.
- A 5-year average of 13163000.0 and a median of 12798000.0 in 2023 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations sank 219.91% in 2022 and soared 34.32% in 2024, its largest moves.
- Tracing DSGN's Cash from Operations over 5 years: stood at 15091000.0 in 2022, then climbed by 15.19% to 12798000.0 in 2023, then gained by 22.96% to 9860000.0 in 2024, then declined by 21.36% to 11966000.0 in 2025, then tumbled by 37.31% to 16431000.0 in 2026.
- Business Quant data shows DSGN's Cash from Operations at 16431000.0 in Q1 2026, 11966000.0 in Q4 2025, and 11162000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 201.34 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -354.17 Mn |
| 10 | Design Therapeutics | 735.98 Mn | 513.16 Mn | - | -16.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.43 Mn |
| Mar 31, 2026 | -16.43 Mn |
| Dec 31, 2025 | -11.97 Mn |
| Dec 31, 2025 | -11.97 Mn |
| Sep 30, 2025 | -11.16 Mn |
| Sep 30, 2025 | -11.16 Mn |
| Jun 30, 2025 | -14.44 Mn |
| Jun 30, 2025 | -14.44 Mn |
| Mar 31, 2025 | -16.79 Mn |
| Mar 31, 2025 | -16.79 Mn |
| Dec 31, 2024 | -9.86 Mn |
| Dec 31, 2024 | -9.86 Mn |
| Sep 30, 2024 | -9.55 Mn |
| Sep 30, 2024 | -9.55 Mn |
| Jun 30, 2024 | -11.26 Mn |
| Jun 30, 2024 | -11.26 Mn |
| Mar 31, 2024 | -12.44 Mn |
| Mar 31, 2024 | -12.44 Mn |
| Dec 31, 2023 | -12.80 Mn |
| Dec 31, 2023 | -12.80 Mn |